focus -WSS

focus

author：explore 2025-08-04 12:29:19 - browse：16

Is there a cure for allergies? Has the FDA become too flexible? And which drugs make you muscular?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Recorded live from from the STAT Breakthrough Summit East in New York City, we discuss some event highlights, including words from CRISPR pioneer Feng Zhang and Regeneron Pharmaceuticals head scientist George Yancopoulos. We also discuss the latest news in the life sciences, including a twist in the GLP-1 story, the cost of gene therapy, and, of course, pie.

For more on what we cover, here’s our full Summit coverage; here’s more on Medicare and GLP-1s; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Kaiser's Risant Health gobbled up Geisinger. Who is next?

explore

WSS

Venture capital firm's plans to take over Akron hospital face hurdles

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Zyn nicotine pouches become unlikely player in latest culture war

Venture capital firm's plans to take over Akron hospital face hurdles

The Affordable Care Act has saved billions in health care costs

Let's speed up science by embracing open access publishing

Wikipedia

focus

focus

At least 13 dead in Texas as scorching temps continue

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Intellia reports positive results for its CRISPR

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How to increase colonoscopy rates? Looks like an AI can help

Apple is now the first public company to be valued at $3 trillion

Biogen walks away from Aduhelm, years after polarizing approval

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

entertainment

Medicare drug price negotiation legal challenge met with skepticism

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Biogen walks away from Aduhelm, years after polarizing approval

Why Medicare shouldn’t cover every FDA

Why you shouldn’t ask, “What country has the best health care?”

knowledge

knowledge

explore

focus